Uveitis refers to a group of intraocular inflammatory diseases that cause 10% to 15% of blindness in the developed world.1- 4 Despite advances in immunosuppressive treatments, corticosteroids remain the mainstay of therapy.5,6 Many patients, however, are intolerant of or resistant to systemic steroids. Topical corticosteroids administered as eye drops are better tolerated than systemic corticosteroids but are typically only effective for anterior uveitis.5 Unfortunately, most of the severe vision loss related to uveitis occurs in patients with intermediate or posterior uveitis, in which the inflammation involves the vitreous and retina.5 Previously, these patients required systemic therapy, either with corticosteroids or other immunosuppressive agents, to control their ocular inflammation.5
Lowder C, Belfort R, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li X, Cui H, Whitcup SM, Ozurdex HURON Study Group. Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis. Arch Ophthalmol. 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.